{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:33:03Z","timestamp":1772253183454,"version":"3.50.1"},"reference-count":52,"publisher":"Sociedade Brasileira de Cardiologia","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Bras. Cardiol."],"abstract":"<jats:p>Resumo  Fundamento: A doen\u00e7a por coronav\u00edrus 2019 (COVID-19) est\u00e1 associada \u00e0 hipercoagulabilidade. Permanece incerto se a anticoagula\u00e7\u00e3o cont\u00ednua para fibrila\u00e7\u00e3o atrial (FA) em pacientes que posteriormente contraem COVID-19 melhora os desfechos cl\u00ednicos.  Objetivos: Comparar a anticoagula\u00e7\u00e3o oral cr\u00f4nica com aus\u00eancia de anticoagula\u00e7\u00e3o pr\u00e9via em pacientes com FA que contra\u00edram uma infec\u00e7\u00e3o por COVID-19 em rela\u00e7\u00e3o aos desfechos de mortalidade por todas as causas, mortalidade por COVID-19, admiss\u00e3o em unidade de terapia intensiva (UTI) e hospitaliza\u00e7\u00e3o.  M\u00e9todos: Buscamos sistematicamente no PubMed, Embase e Cochrane Library estudos eleg\u00edveis desde o in\u00edcio at\u00e9 dezembro de 2022. Inclu\u00edmos estudos que compararam desfechos de COVID-19 em pacientes com e sem anticoagula\u00e7\u00e3o cr\u00f4nica pr\u00e9via para FA. Foram agrupadas raz\u00f5es de risco (RR) com intervalos de confian\u00e7a (IC) de 95% por meio de um modelo de efeitos aleat\u00f3rios. O n\u00edvel de signific\u00e2ncia foi estabelecido em p &lt; 0,05. As avalia\u00e7\u00f5es da qualidade e do risco de vi\u00e9s foram realizadas de acordo com as recomenda\u00e7\u00f5es da Cochrane.  Resultados: Foram identificados 10 estudos abrangendo 1.177.858 pacientes com COVID-19 e FA, dos quais 893.772 (75,9%) estavam em anticoagula\u00e7\u00e3o cr\u00f4nica pr\u00e9via para FA. Em pacientes com COVID-19, a anticoagula\u00e7\u00e3o cr\u00f4nica para FA reduziu significativamente a mortalidade por todas as causas (RR 0,75; IC 95% 0,57 a 0,99; p = 0,048; I2 = 89%) e a mortalidade relacionada \u00e0 COVID-19 (RR 0,76; IC 95% 0,72 a 0,79; p &lt; 0,001; I2 = 0%) quando comparada com a aus\u00eancia de anticoagula\u00e7\u00e3o pr\u00e9via. Em contrapartida, n\u00e3o houve diferen\u00e7a entre os grupos em rela\u00e7\u00e3o \u00e0 hospitaliza\u00e7\u00e3o (RR 1,08; IC 95% 0,82 a 1,41; p = 0,587; I2 = 95%) ou interna\u00e7\u00e3o em UTI (RR 0,86; IC 95% 0,68 a 1,09; p = 0,216; I2 = 69%).  Conclus\u00f5es: Nesta metan\u00e1lise, a anticoagula\u00e7\u00e3o cr\u00f4nica para pacientes com FA que contra\u00edram COVID-19 foi associada a taxas significativamente mais baixas de mortalidade por todas as causas e mortalidade relacionada \u00e0 COVID-19 em compara\u00e7\u00e3o com a aus\u00eancia de anticoagula\u00e7\u00e3o anterior.<\/jats:p>","DOI":"10.36660\/abc.20230470","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T14:50:52Z","timestamp":1716994252000},"source":"Crossref","is-referenced-by-count":0,"title":["Anticoagula\u00e7\u00e3o Cr\u00f4nica em Pacientes com Fibrila\u00e7\u00e3o Atrial e COVID-19: Uma Revis\u00e3o Sistem\u00e1tica e Metan\u00e1lise"],"prefix":"10.36660","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-7762","authenticated-orcid":false,"given":"Isabela","family":"Landsteiner","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital,  EUA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"Universidade de Fortaleza,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8174-3866","authenticated-orcid":false,"given":"Nicole","family":"Felix","sequence":"additional","affiliation":[{"name":"Universidade Federal de Campina Grande,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-2445","authenticated-orcid":false,"given":"Douglas Mesadri","family":"Gewehr","sequence":"additional","affiliation":[{"name":"Instituto do Cora\u00e7\u00e3o de Curitiba,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7605","authenticated-orcid":false,"given":"Rhanderson","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School Boston,  EUA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","series-title":"Coronavirus disease (COVID-19). [Internet]","year":"2023"},{"key":"ref2","series-title":"COVID-19 dashboard. [Internet]","year":"2023"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19","volume":"383","author":"Ackermann M","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy Findings and Venous Thromboembolism in Patients with COVID-19: A Prospective Cohort Study","volume":"173","author":"Wichmann D","year":"2020","journal-title":"Ann Intern Med"},{"key":"ref5","series-title":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. [Internet]","year":"2023"},{"key":"ref6","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 [Internet]","author":"Higgins JPT","year":"2023"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions","volume":"355","author":"Sterne JA","year":"2016","journal-title":"BMJ"},{"issue":"20","key":"ref9","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A Modified Test for Small-Study Effects in Meta-Analyses of Controlled Trials with Binary Endpoints","volume":"25","author":"Harbord RM","year":"2006","journal-title":"Stat Med"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/sim.2688","article-title":"A Comparison of Heterogeneity Variance Estimators in Combining Results of Studies","volume":"26","author":"Sidik K","year":"2007","journal-title":"Stat Med"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying Heterogeneity in a Meta-Analysis","volume":"21","author":"Higgins JP","year":"2002","journal-title":"Stat Med"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting Meta-Analyses in R with the Metafor Package","volume":"36","author":"Viechtbauer W","year":"2010","journal-title":"J. Stat. Soft"},{"key":"ref13","article-title":"Dmetar: Companion R Package For The Guide \"Doing Meta-Analysis in R\"","author":"Harrer H","year":"2019","journal-title":"R package version 0.0.9000. [Internet]"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to Perform a Meta-Analysis with R: A Practical Tutorial","volume":"22","author":"Balduzzi S","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"ref15","series-title":"Ggplot, Elegant Graphics for Data Analysis","author":"Wickham H","year":"2009","edition":"2th ed."},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH - A Graphical Display of Study Heterogeneity","volume":"3","author":"Olkin I","year":"2012","journal-title":"Res Synth Methods"},{"issue":"1","key":"ref17","first-page":"100","article-title":"Algorithm AS 136: A K-Means Clustering Algorithm","volume":"28","author":"Hartigan JA","year":"1979","journal-title":"J R Stat Soc"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1145\/3068335","article-title":"DBSCAN Revisited, Revisited: Why and How You Should (Still) Use DBSCAN","volume":"42","author":"Schubert E","year":"2017","journal-title":"ACM Trans. Database Syst"},{"issue":"458","key":"ref19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1198\/016214502760047131","article-title":"Model-Based Clustering, Discriminant Analysis, and Density Estimation","volume":"97","author":"Fraley C","year":"2002","journal-title":"J Am Stat Assoc"},{"issue":"18","key":"ref20","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/sim.1221","article-title":"A Graphical Method for Exploring Heterogeneity in Meta-Analyses: Application to a Meta-Analysis of 65 Trials","volume":"21","author":"Baujat B","year":"2002","journal-title":"Stat Med"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and Influence Diagnostics for Meta-Analysis","volume":"1","author":"Viechtbauer W","year":"2010","journal-title":"Res Synth Methods"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2021.05.006","article-title":"Protective Effect of Oral Anticoagulant Drugs in Atrial Fibrillation Patients Admitted for COVID-19: Results from the CORIST Study","volume":"203","author":"Ageno W","year":"2021","journal-title":"Thromb Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijcard.2020.12.024","article-title":"Reduction in All-Cause Mortality in COVID-19 Patients on Chronic Oral Anticoagulation: A Population-Based Propensity Score Matched Study","volume":"329","author":"Denas G","year":"2021","journal-title":"Int J Cardiol"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/joim.13205","article-title":"Direct Oral Anticoagulant Use and Risk of Severe COVID-19","volume":"289","author":"Flam B","year":"2021","journal-title":"J Intern Med"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/a-1503-3875","article-title":"COVID-19 and Atrial Fibrillation in Older Patients: Does Oral Anticoagulant Therapy Provide a Survival Benefit?-An Insight from the GeroCovid Registry","volume":"122","author":"Fumagalli S","year":"2022","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.medcli.2022.01.008","article-title":"Mortality Risk Factors in Patients with SARS-CoV-2 Infection and Atrial Fibrillation: Data from the SEMI-COVID-19 Registry","volume":"159","author":"G\u00f3mez JA","year":"2022","journal-title":"Med Clin"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/heartjnl-2021-320325","article-title":"Evaluation of Antithrombotic Use and COVID-19 Outcomes in a Nationwide Atrial Fibrillation Cohort","volume":"108","author":"Handy A","year":"2022","journal-title":"Heart"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/S0735-1097(22)02789-9","article-title":"Pre-Admission Oral Anticoagulation is Associated with Fewer Thrombotic Complications in Patients Admitted With Covid-19","volume":"79","author":"Louis D","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7325060","DOI":"10.1155\/2022\/7325060","article-title":"Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry","volume":"2022","author":"Rivera-Caravaca JM","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"720","key":"ref30","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.3399\/BJGP.2021.0689","article-title":"Association between Oral Anticoagulants and COVID-19-Related Outcomes: A Population-Based Cohort Study","volume":"72","author":"Wong AY","year":"2022","journal-title":"Br J Gen Pract"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0735-1097(22)03133-3","article-title":"The Impact of Oral Anticoagulants on the Outcomes of Covid-19 Patients with a History of Hf and Atrial Fibrillation","volume":"79","author":"Zadeh AV","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"g2116","DOI":"10.1136\/bmj.g2116","article-title":"Anticoagulation in Atrial Fibrillation","volume":"348","author":"Steinberg BA","year":"2014","journal-title":"BMJ"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-Analysis: Antithrombotic Therapy to Prevent Stroke in Patients who Have Nonvalvular Atrial Fibrillation","volume":"146","author":"Hart RG","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9989","key":"ref35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 Year Trends in Atrial Fibrillation Prevalence, Incidence, Risk Factors, and Mortality in the Framingham Heart Study: A Cohort Study","volume":"386","author":"Schnabel RB","year":"2015","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjcard.2021.01.010","article-title":"Meta-Analysis of Atrial Fibrillation in Patients with COVID-19","volume":"144","author":"Yang H","year":"2021","journal-title":"Am J Cardiol"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19","volume":"385","author":"Lawler PR","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-Risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos AC","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"10291","key":"ref39","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus Prophylactic Anticoagulation for Patients Admitted to Hospital with COVID-19 and Elevated D-Dimer Concentration (ACTION): An Open-Label, Multicentre, Randomised, Controlled Trial","volume":"397","author":"Lopes RD","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11239-022-02643-3","article-title":"Thromboembolic Prevention and Anticoagulant Therapy During the COVID-19 Pandemic: Updated Clinical Guidance from the Anticoagulation Forum","volume":"54","author":"Barnes GD","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1182\/bloodadvances.2022007561","article-title":"American Society of Hematology Living Guidelines on the Use of Anticoagulation for Thromboprophylaxis in Patients with COVID-19: January 2022 Update on the Use of Therapeutic-Intensity Anticoagulation in Acutely Ill Patients","volume":"6","author":"Cuker A","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hrtlng.2020.10.009","article-title":"Pattern of Anticoagulation Prescription for Patients with Covid-19 Acute Respiratory Distress Syndrome Admitted to ICU","volume":"50","author":"Nadeem R","year":"2021","journal-title":"Does it Impact Outcome? Heart Lung"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s13054-020-03375-7","article-title":"Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients","volume":"24","author":"Jonmarker S","year":"2020","journal-title":"Crit Care"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5144\/0256-4947.2020.462","article-title":"Therapeutic Dosing of Low-Molecular-Weight Heparin May Decrease Mortality in Patients with Severe COVID-19 Infection","volume":"40","author":"Canoglu K","year":"2020","journal-title":"Ann Saudi Med"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2020.10.031","article-title":"The Effect of Anticoagulation on Clinical Outcomes in Novel Coronavirus (COVID-19) Pneumonia in a U.S. Cohort","volume":"197","author":"Lynn L","year":"2021","journal-title":"Thromb Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus Prophylactic Anticoagulation for Severe COVID-19: A Randomized Phase II Clinical Trial (HESACOVID)","volume":"196","author":"Lemos ACB","year":"2020","journal-title":"Thromb Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"889999","DOI":"10.3389\/fsurg.2022.889999","article-title":"Immuno-Thrombotic Complications of COVID-19: Implications for Timing of Surgery and Anticoagulation","volume":"9","author":"Bunch CM","year":"2022","journal-title":"Front Surg"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"ref49","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1213\/ANE.0000000000002798","article-title":"Statistical Significance versus Clinical Importance of Observed Effect Sizes: What do P Values and Confidence Intervals Really Represent?","volume":"126","author":"Schober P","year":"2018","journal-title":"Anesth Analg"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"11116","DOI":"10.1038\/s41598-022-15287-3","article-title":"Characteristics and Mortality of 561,379 Hospitalized COVID-19 Patients in Germany Until December 2021 Based on Real-Life Data","volume":"12","author":"Kloka JA","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"ref51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why Most Published Research Findings are False","volume":"2","author":"Ioannidis JP","year":"2005","journal-title":"PLoS Med"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jchf.2021.01.009","article-title":"Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction","volume":"9","author":"Lin AY","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":["Chronic Anticoagulation in Patients with Atrial Fibrillation and COVID-19: A Systematic Review and Meta-Analysis"],"link":[{"URL":"https:\/\/abccardiol.org\/wp-content\/uploads\/articles_xml\/0066-782X-abc-121-3-e20230470\/0066-782X-abc-121-3-e20230470.x47225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T14:51:10Z","timestamp":1716994270000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/anticoagulacao-cronica-em-pacientes-com-fibrilacao-atrial-e-covid-19-uma-revisao-sistematica-e-metanalise\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"alternative-id":["S0066-782X2024000300306"],"URL":"https:\/\/doi.org\/10.36660\/abc.20230470","relation":{"is-translation-of":[{"id-type":"doi","id":"10.36660\/abc.20230470i","asserted-by":"subject"},{"id-type":"doi","id":"10.36660\/abc.20230470i","asserted-by":"object"}]},"ISSN":["1678-4170","0066-782X"],"issn-type":[{"value":"1678-4170","type":"electronic"},{"value":"0066-782X","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e20230470"}}